Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460991 · ClinicalTrials.gov registry record · Phase 3
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT02460991 is a Phase 3 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 2 participants.
The verdict
NCT02460991, a Phase 3 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS). Participants in the study will be randomly assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the study participants' outcomes (medical condition) after being treated with ONCO-DOX and compare it to those treated with sorafenib alone.
Interventions
- DRUG Sorafenib
- DEVICE DEB-TACE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02460991
The ClinicalTrials.gov registry entry for NCT02460991 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT02460991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02460991 about?
NCT02460991 is a clinical study titled "A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma". This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS). Participants in the study will be randomly assigned to receive either ONCO-DOX or sorafenib treatment. This study will evaluate the study participants' outcomes (...
What is the current status of trial NCT02460991?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2015-11. Estimated completion is 2017-06-05.
What interventions are being tested in trial NCT02460991?
The interventions under investigation include: Sorafenib (DRUG), DEB-TACE (DEVICE).
Who is sponsoring clinical trial NCT02460991?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.